A detailed history of Russell Investments Group, Ltd. transactions in Exact Sciences Corp stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 232,698 shares of EXAS stock, worth $11.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
232,698
Previous 241,540 3.66%
Holding current value
$11.9 Million
Previous $10.2 Million 55.26%
% of portfolio
0.02%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$42.43 - $70.83 $375,166 - $626,278
-8,842 Reduced 3.66%
232,698 $15.8 Million
Q2 2024

Aug 08, 2024

BUY
$41.33 - $74.26 $838,957 - $1.51 Million
20,299 Added 9.18%
241,540 $10.2 Million
Q1 2024

May 08, 2024

BUY
$56.27 - $73.77 $1.39 Million - $1.82 Million
24,625 Added 12.52%
221,241 $15.3 Million
Q4 2023

Feb 05, 2024

BUY
$59.06 - $75.72 $2.48 Million - $3.18 Million
41,978 Added 27.15%
196,616 $14.5 Million
Q3 2023

Nov 13, 2023

BUY
$65.94 - $99.04 $8.06 Million - $12.1 Million
122,248 Added 377.43%
154,638 $10.5 Million
Q2 2023

Aug 10, 2023

SELL
$62.68 - $95.05 $302,117 - $458,141
-4,820 Reduced 12.95%
32,390 $3.04 Million
Q1 2023

May 09, 2023

BUY
$47.19 - $70.77 $248,313 - $372,391
5,262 Added 16.47%
37,210 $2.52 Million
Q4 2022

Feb 08, 2023

SELL
$30.35 - $53.15 $10,865 - $19,027
-358 Reduced 1.11%
31,948 $1.58 Million
Q3 2022

Nov 04, 2022

SELL
$31.97 - $49.37 $172,861 - $266,943
-5,407 Reduced 14.34%
32,306 $1.06 Million
Q2 2022

Jul 29, 2022

SELL
$35.61 - $76.23 $19.5 Million - $41.8 Million
-548,616 Reduced 93.57%
37,713 $1.5 Million
Q1 2022

May 05, 2022

BUY
$57.56 - $82.54 $8.52 Million - $12.2 Million
148,057 Added 33.78%
586,329 $41 Million
Q4 2021

Jan 21, 2022

BUY
$72.5 - $100.68 $12.9 Million - $18 Million
178,478 Added 68.7%
438,272 $34.1 Million
Q3 2021

Nov 08, 2021

BUY
$90.24 - $124.05 $5.07 Million - $6.97 Million
56,208 Added 27.61%
259,794 $24.7 Million
Q2 2021

Aug 04, 2021

SELL
$93.66 - $139.27 $721,556 - $1.07 Million
-7,704 Reduced 3.65%
203,586 $25.4 Million
Q1 2021

May 10, 2021

SELL
$116.57 - $155.01 $16.5 Million - $21.9 Million
-141,356 Reduced 40.08%
211,290 $27.7 Million
Q4 2020

Feb 08, 2021

SELL
$99.61 - $142.12 $241,554 - $344,641
-2,425 Reduced 0.68%
352,646 $46.9 Million
Q3 2020

Nov 09, 2020

SELL
$72.92 - $102.01 $1.93 Million - $2.7 Million
-26,428 Reduced 6.93%
355,071 $36.2 Million
Q2 2020

Aug 05, 2020

SELL
$55.75 - $92.75 $1.83 Million - $3.04 Million
-32,790 Reduced 7.91%
381,499 $33.2 Million
Q1 2020

May 06, 2020

BUY
$37.9 - $104.44 $8.9 Million - $24.5 Million
234,835 Added 130.86%
414,289 $24 Million
Q4 2019

Jan 29, 2020

SELL
$77.66 - $99.74 $8.51 Million - $10.9 Million
-109,570 Reduced 37.91%
179,454 $16.6 Million
Q3 2019

Nov 01, 2019

SELL
$90.37 - $122.49 $6.42 Million - $8.7 Million
-71,028 Reduced 19.73%
289,024 $26.3 Million
Q2 2019

Aug 09, 2019

SELL
$89.51 - $118.04 $3.42 Million - $4.52 Million
-38,259 Reduced 9.61%
360,052 $42.1 Million
Q1 2019

May 13, 2019

SELL
$61.98 - $96.5 $3.19 Million - $4.97 Million
-51,508 Reduced 11.45%
398,311 $34.2 Million
Q4 2018

Feb 11, 2019

SELL
$56.04 - $82.66 $9.08 Million - $13.4 Million
-162,093 Reduced 26.49%
449,819 $28.1 Million
Q3 2018

Oct 26, 2018

BUY
$48.29 - $80.6 $2.65 Million - $4.42 Million
54,863 Added 9.85%
611,912 $47.9 Million
Q2 2018

Aug 08, 2018

SELL
$37.84 - $69.96 $2.63 Million - $4.87 Million
-69,576 Reduced 11.1%
557,049 $33.4 Million
Q1 2018

May 11, 2018

BUY
$39.82 - $57.53 $4.99 Million - $7.2 Million
125,208 Added 24.97%
626,625 $25.2 Million
Q4 2017

Feb 06, 2018

BUY
$46.49 - $60.51 $8.13 Million - $10.6 Million
174,948 Added 53.59%
501,417 $27.4 Million
Q3 2017

Nov 07, 2017

BUY
$37.05 - $47.12 $12.1 Million - $15.4 Million
326,469
326,469 $15.4 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $9.01B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.